STAGE IV LUNG CANCER AJCC V8

This early-phase trial is testing whether combining two drugs—brigatinib and bevacizumab—can help people with a specific kind of lung cancer (ALK-positive non-small cell lung cancer) whose cancer has gotten worse despite previous ALK-targeted therapy. The study involves just 5 pa…

This phase II trial tests a DNA vaccine called STEMVAC in 5 people with stage IV non-small cell lung cancer. The vaccine gives the body instructions to make parts of five proteins found on lung cancer cells, with the goal of activating immune cells to attack the tumor. Participan…

This study is testing a combination of drugs and radiation for people with extensive-stage small cell lung cancer (ES-SCLC) who haven't been treated yet. The drugs include olaparib (which blocks cancer cells from repairing themselves), durvalumab (which helps the immune system at…

This early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…

This early-phase trial tests a drug called WSD0922-FU in 56 people with certain brain cancers (glioblastoma, anaplastic astrocytoma) or lung cancer that has spread to the brain or spinal cord. The drug blocks a protein called EGFR that helps cancers grow, and is designed to reach…

This study tested two drugs, osimertinib and bevacizumab, in people with a specific type of lung cancer (EGFR mutation-positive) that had spread to the brain. The goal was to see if adding bevacizumab to osimertinib could help control the cancer longer. The trial enrolled 5 parti…

This early-phase study tests two experimental drugs, sapanisertib and telaglenastat, in people with advanced non-small cell lung cancer that has spread to the brain or other areas. The main goal is to find the safest dose and see if the combination can shrink tumors or slow the d…

This study tests whether adding an experimental drug (N-803) to the immunotherapy pembrolizumab can help control advanced non-small cell lung cancer better than standard treatments. The drug combo aims to activate natural killer cells and boost the immune system's attack on cance…

This early-phase trial is testing a combination of all-trans retinoic acid (ATRA), a substance made from vitamin A, and the immunotherapy drug atezolizumab in people with advanced non-small cell lung cancer that has spread or come back. The main goal is to find the safest dose an…

This early-phase trial is testing the safety and best dose of a drug called berzosertib when given together with whole brain radiation therapy. The study includes 15 people with lung cancer that has spread to the brain. The goal is to find out if this combination is safe enough t…

This phase I/II trial is testing whether adding the CIMAvax vaccine (which targets a growth factor that tumors need) to standard immunotherapy drugs (nivolumab or pembrolizumab) can better control advanced non-small cell lung cancer and squamous head/neck cancer. The study involv…

This early-phase trial tests a new treatment for people with advanced non-small cell lung cancer that has stopped responding to standard immunotherapy. The treatment uses immune cells from umbilical cord blood that are genetically modified to better recognize and attack cancer ce…

This early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…

This study tests a combination of two drugs—pembrolizumab (an immunotherapy) and trametinib (a targeted therapy)—in people with advanced non-small cell lung cancer that has come back or spread. The goal is to see if the combination is safe and can shrink or control tumors. Partic…

This early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…

This early-phase study tests the safety and best dose of a new drug, minnelide, when given with the standard drug osimertinib for people with advanced EGFR-mutated non-small cell lung cancer. The trial enrolls about 8 adults whose cancer has spread or cannot be removed by surgery…

This study tests whether adding local treatments like surgery or radiation to a combination of two immunotherapy drugs (nivolumab and ipilimumab) helps people with stage IV non-small cell lung cancer live longer compared to immunotherapy alone. About 339 participants who have not…

This early-phase study tests a new drug (BAY 1895344) combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, including small cell lung cancer, neuroendocrine cancer, and pancreatic cancer. The goal is to find the safest dose and check …

This study tests whether combining two drugs, atezolizumab and cobimetinib, can help people with advanced non-small cell lung cancer whose tumors stopped responding to standard immunotherapy. About 51 adults with metastatic or recurrent lung cancer will receive the combination. T…

This study tests a combination of drugs (berzosertib, carboplatin, gemcitabine, and pembrolizumab) in people with advanced squamous non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combo helps control the cancer longer than standard tre…

This study compares two treatments for lung lesions in people with non-small cell lung cancer, sarcoma, or colorectal cancer that has spread. One treatment uses microwaves to heat and kill tumor cells, while the other is a surgery to remove a small piece of lung. Researchers want…

This study tests two treatment plans for people with advanced non-squamous non-small cell lung cancer. One group gets immunotherapy (pembrolizumab) alone first, then chemo plus or minus immunotherapy later. The other group gets immunotherapy plus chemo from the start, followed by…

This study looks at whether using focused radiation (stereotactic radiosurgery) only on the brain tumors, instead of the whole brain, can help preserve thinking and memory in people with small cell lung cancer that has spread to the brain. About 55 participants will receive this …

This early-phase trial tested the safety of combining two drugs, nivolumab and cabozantinib, in 8 people with HIV who also have advanced solid tumors. The goal was to see if the combination is safe and can shrink or stabilize the cancer. The study focused on finding the right dos…

This early trial tests combining the targeted drug brigatinib with local treatments like surgery or radiation for people with advanced ALK-positive non-small cell lung cancer. The goal is to see if this approach is safe and helps control the cancer longer. About 35 participants w…

This study tests a combination of three drugs (niraparib, temozolomide, and atezolizumab) in people with advanced solid tumors or extensive-stage small cell lung cancer that has responded to initial chemotherapy. The goal is to find the safest dose and see if the combination help…

This study tests whether a lung cancer drug called atezolizumab can be safely given as a shot under the skin at home, with doctors monitoring patients through video calls. It involves 5 adults with non-small cell lung cancer. The goal is to see if this home-based approach is prac…

This study looks at whether adding surgery or radiation to the targeted drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 173 participants will receive either osimertinib alone or osimertinib plus lo…

This study tests whether a combination of two drugs (ramucirumab and pembrolizumab) works better than standard chemotherapy for people with advanced or returning non-small cell lung cancer who have already tried immunotherapy. About 838 participants will be randomly assigned to o…

This early-phase study tests a new drug combination for people with advanced ALK-positive non-small cell lung cancer. The goal is to find the best dose of ensartinib when given with standard chemotherapy and a targeted antibody. About 12 participants will receive the treatment to…

This study tests the safety and best dose of adding telaglenastat to the standard drug osimertinib for people with stage IV non-small cell lung cancer that has a specific EGFR mutation. The two drugs work together to block enzymes that cancer cells need to grow. The trial involve…

This study tests a drug called selpercatinib in people with advanced or returning non-small cell lung cancer that has a specific gene change (RET fusion). The drug works by blocking signals that help cancer cells grow. About 124 participants will receive the treatment to see if i…

This study tests a combination of three drugs (chemotherapy, anti-angiogenesis, and immunotherapy) in 30 adults with advanced non-small cell lung cancer that worsened after standard treatments. The goal is to see if this triple therapy is safe and works better than current option…

This study tests a new drug combination for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). The two drugs, LY3295668 and osimertinib, work by blocking enzymes that help cancer cells grow. The goal is to find the safest dose and see if…

This early-phase trial studies the safety and best dose of adding necitumumab to osimertinib for people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. About 138 participants will receive the combination to see if it is tolerable a…

This study tests two new treatments—cabozantinib alone or with nivolumab—against standard chemotherapy for people with advanced non-squamous lung cancer that has returned. The goal is to see if these combinations can slow cancer growth better than current options. About 117 adult…

This phase 2 study tests a new drug (pevonedistat) combined with two standard chemotherapies (carboplatin and paclitaxel) in 27 adults with advanced non-small cell lung cancer that has not responded to immunotherapy. The goal is to see if this combination can shrink or control th…

This study looks at whether adding radiation therapy to standard immunotherapy (with or without chemo) helps people with advanced non-small cell lung cancer that lacks the PD-L1 marker. About 427 adults with stage IIIB, IIIC, or IV cancer will be randomly assigned to get either t…

This study tests a drug called AMG 510 in people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation). The drug is designed to block the cancer's growth signal. About 116 participants will receive the treatment to see if it can shrink tumors and slow …

This study tests an online program called BREATHE for women with non-small cell lung cancer. The program uses mindfulness, compassion, and emotional processing to help improve social well-being and reduce distress. About 70 women will participate, and the main goal is to see if t…

This study looks at whether a drug called anamorelin can help improve appetite and stop weight loss in people with advanced lung cancer who have lost their appetite and are losing weight. About 25 participants will take either the drug or a placebo and share their experiences thr…

This study tests a simple conversation tool designed to help people with lung cancer understand their options and make decisions that match their values. About 98 patients will use the tool during their care. The goal is to see if it reduces anxiety, regret, and confusion, and im…

This study looks at whether updating radiation treatment plans at set times (adaptive planning) can lower side effects like lung inflammation in people with stage II-IV non-small cell lung cancer. About 34 participants will receive standard radiation and immunotherapy, but their …

This study tests a nurse-led program designed to help people with advanced lung or gynecologic cancer cope with fears about their future. About 42 participants will try the program, which includes sessions and home activities. The goal is to see if the program is practical and he…

This early-stage study tests whether giving a single, very focused dose of radiation after lung cancer surgery is safe and causes fewer side effects than standard weeks-long radiation. It involves 50 adults with non-small cell lung cancer who had surgery but still have cancer cel…

This study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…

This pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study tests whether watching a short video helps people with metastatic cancer understand what tumor genomic testing is and why it matters. About 243 adults with advanced cancer will watch the video and answer questions before and after. The goal is to see if the video impro…